Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BLUE Wedbush Reiterates Outperform On Bluebird Bio Following LentiGlobin Data Release http://www.smarteranalyst.com/2014/12/10/wedbush-reiterates-outperform-on-bluebird-bio-following-lentiglobin-data-release/
$CBST Wedbush Comments On Cubist Pharmaceuticals Following Patent Setback http://www.smarteranalyst.com/2014/12/10/wedbush-comments-on-cubist-pharmaceuticals-following-patent-setback/
$CBST Wedbush Comments On Cubist Pharmaceuticals Following Patent Setback http://www.smarteranalyst.com/2014/12/10/wedbush-comments-on-cubist-pharmaceuticals-following-patent-setback/
Another one :)
Canaccord Reiterates Buy On Verizon Communications Following Q4/14 QTD Trends Release
http://www.smarteranalyst.com/2014/12/10/canaccord-reiterates-buy-on-verizon-communications-following-q414-qtd-trends-release/
$SNSS Roth Capital Reiterates Neutral On Sunesis Following Data From Phase I/II AML/MDS Study http://www.smarteranalyst.com/2014/12/09/roth-capital-reiterates-neutral-on-sunesis-following-data-from-phase-iii-amlmds-study/
$SNSS Roth Capital Reiterates Neutral On Sunesis Following Data From Phase I/II AML/MDS Study http://www.smarteranalyst.com/2014/12/09/roth-capital-reiterates-neutral-on-sunesis-following-data-from-phase-iii-amlmds-study/
$ONCS Maxim Comments On OncoSec Medical As It Takes IL-12 Immunopulse To Head And Neck Cancer http://www.smarteranalyst.com/2014/12/09/maxim-comments-on-oncosec-medical-as-it-takes-il-12-immunopulse-to-head-and-neck-cancer/
$ONCS Maxim Comments On OncoSec Medical As It Takes IL-12 Immunopulse To Head And Neck Cancer http://www.smarteranalyst.com/2014/12/09/maxim-comments-on-oncosec-medical-as-it-takes-il-12-immunopulse-to-head-and-neck-cancer/
$TGTX Roth Capital Reiterates Buy On TG Therapeutics Following TG-1101 Update http://www.smarteranalyst.com/2014/12/09/roth-capital-reiterates-buy-on-tg-therapeutics-following-tg-1101-update/
$CBST Wedbush Raises Cubist Price Target On The Back Of Merck Acquisition Value http://www.smarteranalyst.com/2014/12/09/wedbush-raises-cubist-price-target-on-the-back-of-merck-acquisition-value/
$CBST Wedbush Raises Cubist Price Target On The Back Of Merck Acquisition Value http://www.smarteranalyst.com/2014/12/09/wedbush-raises-cubist-price-target-on-the-back-of-merck-acquisition-value/
$CELG Cowen Maintains Outperform On Celgene Following ASH Meeting; Keeps $110 PT http://www.smarteranalyst.com/2014/12/09/cowen-maintains-outperform-on-celgene-following-ash-meeting-keeps-110-pt/
$CELG Cowen Maintains Outperform On Celgene Following ASH Meeting; Keeps $110 PT http://www.smarteranalyst.com/2014/12/09/cowen-maintains-outperform-on-celgene-following-ash-meeting-keeps-110-pt/
$ICPT Wedbush Maintains Outperform On Intercept Pharmaceuticals Following PBC Supergroup Meta-Analysis Publication http://www.smarteranalyst.com/2014/12/09/wedbush-maintains-outperform-on-intercept-pharmaceuticals-following-pbc-supergroup-meta-analysis-publication/
$ICPT Wedbush Maintains Outperform On Intercept Pharmaceuticals Following PBC Supergroup Meta-Analysis Publication http://www.smarteranalyst.com/2014/12/09/wedbush-maintains-outperform-on-intercept-pharmaceuticals-following-pbc-supergroup-meta-analysis-publication/
$MEIP Cowen Comments On MEI Pharma Following Phase II Study Of Pracinostat In Front Line Acute Myeloid Leukemia http://www.smarteranalyst.com/2014/12/09/cowen-comments-on-mei-pharma-following-phase-ii-study-of-pracinostat-in-front-line-acute-myeloid-leukemia/
$MEIP Cowen Comments On MEI Pharma Following Phase II Study Of Pracinostat In Front Line Acute Myeloid Leukemia http://www.smarteranalyst.com/2014/12/09/cowen-comments-on-mei-pharma-following-phase-ii-study-of-pracinostat-in-front-line-acute-myeloid-leukemia/
$PSEC MLV Cuts Prospect Capital Price Target On The Back Of Lower Dividend http://www.smarteranalyst.com/2014/12/09/mlv-cuts-prospect-capital-price-target-on-the-back-of-lower-dividend/
$TSLA Tesla Motors Could Fall Another -27%: Analysts http://www.smarteranalyst.com/contributor/2014/12/09/tesla-motors-could-fall-another-27-analysts/
Seattle Genetics: Continued Quality And Breadth Of Data Should Yield Investor Re-Engagement, Says HC Wainwright http://www.smarteranalyst.com/2014/12/09/seattle-genetics-continued-quality-and-breadth-of-data-should-yield-investor-re-engagement-says-h-c-wainwright/
$SNSS Cowen Maintains Outperform On Sunesis Pharmaceuticals Following Investor Meeting At ASH http://www.smarteranalyst.com/2014/12/09/cowen-maintains-outperform-on-sunesis-pharmaceuticals-following-investor-meeting-at-ash/
$SNSS Cowen Maintains Outperform On Sunesis Pharmaceuticals Following Investor Meeting At ASH http://www.smarteranalyst.com/2014/12/09/cowen-maintains-outperform-on-sunesis-pharmaceuticals-following-investor-meeting-at-ash/
$VLO Oppenheimer Cuts Valero Energy Price Target To Reflect Generally Weak Energy Markets http://www.smarteranalyst.com/2014/12/09/oppenheimer-cuts-valero-energy-price-target-to-reflect-generally-weak-energy-markets/
$AGIO Cowen Maintains Outperform On Agios Pharmaceuticals As AG-221 Moving In On Pivotal Trials http://www.smarteranalyst.com/2014/12/09/cowen-maintains-outperform-on-agios-pharmaceuticals-as-ag-221-moving-in-on-pivotal-trials/
$BLRX Maxim Maintains Buy On Biolinerx Following Interim Data For BL-8040 Phase IIa in AML http://www.smarteranalyst.com/2014/12/08/maxim-maintains-buy-on-biolinerx-following-interim-data-for-bl-8040-phase-iia-in-aml/
$BLRX Maxim Maintains Buy On Biolinerx Following Interim Data For BL-8040 Phase IIa in AML http://www.smarteranalyst.com/2014/12/08/maxim-maintains-buy-on-biolinerx-following-interim-data-for-bl-8040-phase-iia-in-aml/
$PSTI Maxim Maintains Buy On Pluristem Following Collaboration Agreement With Hadassah Medical Center http://www.smarteranalyst.com/2014/12/08/maxim-maintains-buy-on-pluristem-following-collaboration-agreement-with-hadassah-medical-center/
$ONCS Maxim Reiterates Buy On OncoSec Medical Following F1Q15 Update http://www.smarteranalyst.com/2014/12/08/maxim-reiterates-buy-on-oncosec-medical-following-f1q15-update/
$ONCS Maxim Reiterates Buy On OncoSec Medical Following F1Q15 Update http://www.smarteranalyst.com/2014/12/08/maxim-reiterates-buy-on-oncosec-medical-following-f1q15-update/
$X Deutsche Bank Reiterates Buy On United States Steel Following Q&A With Management http://www.smarteranalyst.com/2014/12/08/deutsche-bank-reiterates-buy-on-united-states-steel-following-qa-with-management/
$THLD H.C. Wainwright Maintains Buy On Threshold Pharmaceuticals Following TH-302 Phase 1/2 Data http://www.smarteranalyst.com/2014/12/08/h-c-wainwright-maintains-buy-on-threshold-pharmaceuticals-following-th-302-phase-12-data/
$THLD H.C. Wainwright Maintains Buy On Threshold Pharmaceuticals Following TH-302 Phase 1/2 Data http://www.smarteranalyst.com/2014/12/08/h-c-wainwright-maintains-buy-on-threshold-pharmaceuticals-following-th-302-phase-12-data/
$GALE Roth Capital Maintains Buy On Galena Following GALE-401 Phase II Interim Data http://www.smarteranalyst.com/2014/12/08/roth-capital-maintains-buy-on-galena-following-gale-401-phase-ii-interim-data/
Applied Materials Is Attractively Valued Relative To Semicap And Large Cap Semis
http://www.smarteranalyst.com/2014/12/08/applied-materials-is-attractively-valued-relative-to-semicap-and-large-cap-semis/
$CBST Oppenheimer Comments On Cubist Pharmaceuticals As Merck Is Nearing An $8B Takeover http://www.smarteranalyst.com/2014/12/08/oppenheimer-reiterates-outperform-on-cubist-pharmaceuticals-shares-sees-18-downside-for-the-stock/
$CBST Oppenheimer Comments On Cubist Pharmaceuticals As Merck Is Nearing An $8B Takeover http://www.smarteranalyst.com/2014/12/08/oppenheimer-reiterates-outperform-on-cubist-pharmaceuticals-shares-sees-18-downside-for-the-stock/
BMO Raises Apple Price Target As December And March Quarters Could Be Peak Growth Quarters http://www.smarteranalyst.com/2014/12/08/bmo-maintains-outperform-on-apple-shares-sees-8-upside-for-the-stock/
$AAPL BMO Raises Apple Price Target As December And March Quarters Could Be Peak Growth Quarters http://www.smarteranalyst.com/2014/12/08/bmo-maintains-outperform-on-apple-shares-sees-8-upside-for-the-stock/
$CELG We Continue To Like Celgene Shares, Says Cantor http://www.smarteranalyst.com/2014/12/08/cantor-reiterates-buy-on-celgene-corporation-shares-sees-12-upside-for-the-stock/
$CVX Oppenheimer Cuts Chevron Price Target On The Back Of Lower Oil Prices http://www.smarteranalyst.com/2014/12/08/oppenheimer-reiterates-outperform-on-chevron-shares-sees-18-upside-for-the-stock-2/